期刊
PROTEOMICS CLINICAL APPLICATIONS
卷 6, 期 1-2, 页码 42-59出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/prca.201100062
关键词
Biomarker; Plasma; Protein; Selected reaction monitoring; Quantitation
资金
- NHMRC
- Cancer Institute NSW
The widespread clinical adoption of protein biomarkers with diagnostic, prognostic and/or predictive value remains a formidable challenge for the biomedical community. From discovery to validation, the path to biomarkers of clinical relevance abounds with many protein candidates, yet so few concrete examples have been substantiated. In this review, we focus on the recent adoption of selected reaction monitoring (SRM) of plasma proteins in the path to clinical use for a broad range of diseases including cancer, cardiovascular disease, genetic disorders and various metabolic disorders. Recent progress reveals a promising outlook for clinical applications using SRM, which now provides the routine analysis of clinically relevant protein markers at low nanogram per millilitre in plasma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据